Summary
Mucopolysaccharidosis II (MPS II, Hunter syndrome in humans) is an X-linked inherited lysosomal storage disease caused by a deficiency in the lysosomal enzyme iduronate-2-sulfatase (I2S). I2S catalyses a step in the catabolism of glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate, and when it is deficient or absent GAGs accumulate in tissues and organs. Male knockout mice (IdS-KO), which lack the gene coding for I2S, exhibit many of the characteristics seen in the human disease. Compared to wild-type control mice, urine GAG excretion was elevated at 4 weeks of age and remained high throughout the lifespan, and tissue GAG levels were elevated as early as 7 weeks of age. Liver, spleen and other organs were significantly larger in the IdS-KO mice than in the wild-type. Radiographic examination revealed sclerosis and enlargement of the skull at 4 weeks of age and appendicular bone enlargement at 10–13 weeks of age. Micro CT scans showed severe periosteal bone formation at the lateral aspect of the distal tibia and calcification of the calcaneus tendon. This model was used in the development of idursulfase for treatment of MPS II and may continue to be useful in the evaluation of treatment strategies of this chronic and progressive disorder.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Birkenmeier EH, Davisson MT, Beamer WG, et al (1989) Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. J Clin Invest 83: 1258-266.
Cardone M, Polito VA, Pepe S, et al (2006) Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum Mol Genet 15: 1225-236.
Clarke LA, Russell CS, Pownall S, et al (1997) Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-l-iduronidase gene. Hum Mol Genet 6: 503-11.
de Jong JGN, Wevers RA, Laarakkers C, Poorthuis BJ (1989) Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. Clin Chem 35: 1472-477.
de Jong JG, Wevers RA, Liebrand-van SR (1992) Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem 38: 803-07.
Evers M, Saftig P, Schmidt P, et al (1996) Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI. Proc Natl Acad Sci USA 93: 8214-219.
Friso A, Tomanin R, Alba S, et al (2005) Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. J Gen Med 7: 1482-491.
Garcia AR, DeCosta JM, Pan J, Muenzer J, Lamsa JC (2007) Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knockout mouse model of MPS II. Mol Genet Metab 91: 183-90.
Kakkis ED, Schuchman E, He X, et al (2001) Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol Genet Metab 72: 199-08.
Li HH, Yu WH, Rozengurt N, et al (1999) Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding α-N-acetylglucosaminidase. Proc Natl Acad Sci USA 96: 14505-4510.
Muenzer J, Fu H (1999) Targeted disruption of the mouse iduronate sulfatase gene. Am J Genet 65: A427.
Muenzer J, Lamsa JC, Garcia A, Dacosta J, Garcia J, Treco DA (2002) Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl 91: 98-9.
Muenzer J, Wraith JE, Beck M, et al (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8: 465-73.
Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3421–3452.
Spellacy E, Shull RM, Constantopoulos G, Neufeld EF (1983) A canine model of human alpha-l-iduronidase deficiency. Proc Natl Acad Sci USA 80: 6091-095.
Tomatsu S, Orii KO, Vogler C, et al (2003) Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns −/− produced by targeted disruption of the gene defective in Morquio A disease. Hum Mol Genet 12: 3349-358.
Voznyi YV, Keulemans JL, van Diggelen OP (2001) A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J Inherit Metab Dis 24: 675-80.
Wraith JE, Clarke LA, Beck M, et al (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase). J Pediatr 144: 581-88.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicating editor: Markus Grompe
Competing interests: A.R. Garcia, J. Pan and J.C. Lamsa are employees of Shire Human Genetic Therapies, Inc. J. Muenzer has been a consultant to Shire HGT during the development of idursulfase for the treatment of MPS II. Editorial assistance was provided by Edward Weselcouch and was paid for by Shire HGT.
References to electronic databases: Iduronate-2-sulfatase: EC 3.1.6.13. Mucopolysaccharidosis II (Hunter syndrome): OMIM 309900. http://www.hgmd.cf.ac.uk/ac/gene.php?gene=IDS.
Rights and permissions
About this article
Cite this article
Garcia, A.R., Pan, J., Lamsa, J.C. et al. The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome). J Inherit Metab Dis 30, 924–934 (2007). https://doi.org/10.1007/s10545-007-0641-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-007-0641-8